{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T22:07:51Z","timestamp":1750284471193},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T00:00:00Z","timestamp":1703289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T00:00:00Z","timestamp":1703289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s00210-023-02912-9","type":"journal-article","created":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T08:02:16Z","timestamp":1703318536000},"page":"4737-4745","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel kappa opioid receptor agonist ZYKR1: a randomized double-blind placebo-control phase 1 study in healthy adult human participants"],"prefix":"10.1007","volume":"397","author":[{"given":"Kevinkumar A.","family":"Kansagra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taufik","family":"Momin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hardik B.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chintan","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordhan","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok","family":"Ghoghari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harilal V.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deven V.","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,23]]},"reference":[{"issue":"4","key":"2912_CR1","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/jcpt.12404","volume":"41","author":"A Albert-Vartanian","year":"2016","unstructured":"Albert-Vartanian A, Boyd MR, Hall AL, Morgado SJ, Nguyen E, Nguyen VP, Patel SP, Russo LJ, Shao AJ, Raffa RB (2016) Will peripherally restricted kappa-opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? J Clin Pharm Ther 41(4):371\u2013382. https:\/\/doi.org\/10.1111\/jcpt.12404","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"2912_CR2","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1208\/s12248-009-9105-4","volume":"11","author":"JV Aldrich","year":"2009","unstructured":"Aldrich JV, McLaughlin JP (2009) Peptide kappa opioid receptor ligands: potential for drug development. AAPS J. 11(2):312\u201322. https:\/\/doi.org\/10.1208\/s12248-009-9105-4","journal-title":"AAPS J."},{"issue":"12","key":"2912_CR3","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1038\/sj.npp.1300811","volume":"30","author":"G Bart","year":"2005","unstructured":"Bart G, Schluger JH, Borg L, Ho A, Bidlack JM, Kreek MJ (2005) Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology 30(12):2254\u20132262. https:\/\/doi.org\/10.1038\/sj.npp.1300811","journal-title":"Neuropsychopharmacology"},{"issue":"2 Suppl","key":"2912_CR4","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.36076\/ppj.2008\/11\/S105","volume":"11","author":"R Benyamin","year":"2008","unstructured":"Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R (2008) Opioid complications and side effects. Pain Physician 11(2 Suppl):S105\u2013S120","journal-title":"Pain Physician"},{"issue":"2\u20133","key":"2912_CR5","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/s0014-2999(01)01121-9","volume":"423","author":"ER Butelman","year":"2001","unstructured":"Butelman ER, Kreek MJ (2001) Kappa-opioid receptor agonist-induced prolactin release in primates is blocked by dopamine D(2)-like receptor agonists. Eur J Pharmacol 423(2\u20133):243\u2013249. https:\/\/doi.org\/10.1016\/s0014-2999(01)01121-9","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"2912_CR6","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/s0014-2999(99)00640-8","volume":"383","author":"ER Butelman","year":"1999","unstructured":"Butelman ER, Harris TJ, Kreek M (1999) Apparent efficacy of kappa-opioid receptor ligands on serum prolactin levels in rhesus monkeys. Eur J Pharmacol 383(3):305\u2013309. https:\/\/doi.org\/10.1016\/s0014-2999(99)00640-8","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"2912_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000000634","volume":"3","author":"M Cohen","year":"2018","unstructured":"Cohen M, Quintner J, van Rysewyk S (2018) Reconsidering the International Association for the Study of Pain definition of pain. Pain Rep 3(2):e634. https:\/\/doi.org\/10.1097\/PR9.0000000000000634","journal-title":"Pain Rep"},{"issue":"13","key":"2912_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.837671","volume":"20","author":"ML Dalefield","year":"2022","unstructured":"Dalefield ML, Scouller B, Bibi R, Kivell BM (2022) The kappa opioid receptor: a promising therapeutic target for multiple pathologies. Front Pharmacol 20(13):837671. https:\/\/doi.org\/10.3389\/fphar.2022.837671","journal-title":"Front Pharmacol"},{"issue":"7","key":"2912_CR9","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2174\/1381612043453036","volume":"10","author":"DL DeHaven-Hudkins","year":"2004","unstructured":"DeHaven-Hudkins DL, Dolle RE (2004) Peripherally restricted opioid agonists as novel analgesic agents. Curr Pharm Des 10(7):743\u2013757. https:\/\/doi.org\/10.2174\/1381612043453036","journal-title":"Curr Pharm Des"},{"key":"2912_CR10","unstructured":"Dhaliwal A, Gupta M (2023) Physiology, Opioid Receptor. [Updated 2023 Jul 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK546642\/"},{"issue":"1","key":"2912_CR11","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/s0168-8278(00)80187-7","volume":"32","author":"A Gadano","year":"2000","unstructured":"Gadano A, Moreau R, Pessione F, Trombino C, Giuily N, Sinnassamy P, Valla D, Lebrec D (2000) Aquaretic effects of niravoline, a kappa-opioid agonist, in patients with cirrhosis. J Hepatol 32(1):38\u201342. https:\/\/doi.org\/10.1016\/s0168-8278(00)80187-7","journal-title":"J Hepatol"},{"key":"2912_CR12","doi-asserted-by":"publisher","first-page":"122982","DOI":"10.1016\/j.jchromb.2021.122982","volume":"1185","author":"A Ghoghari","year":"2021","unstructured":"Ghoghari A, Bhatt C, Patel K, Jha A, Patel H, Jain M, Momin T, Parmar D, Patel P (2021) Estimation of ZYKR1 in human urine and plasma utilizing LC-MS\/MS positive electrospray ionization; a kappa opioid receptor (KOR) agonist. J Chromatogr B Analyt Technol Biomed Life Sci. 1185:122982. https:\/\/doi.org\/10.1016\/j.jchromb.2021.122982","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci."},{"key":"2912_CR13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/164_2020_399","volume":"271","author":"S Inan","year":"2022","unstructured":"Inan S (2022) Kappa opioid agonist-induced diuresis: characteristics, mechanisms, and beyond. Handb Exp Pharmacol 271:401\u2013417. https:\/\/doi.org\/10.1007\/164_2020_399","journal-title":"Handb Exp Pharmacol"},{"key":"2912_CR14","doi-asserted-by":"publisher","first-page":"174961","DOI":"10.1016\/j.ejphar.2022.174961","volume":"924","author":"MR Jain","year":"2022","unstructured":"Jain MR, Patel RB, Prajapati KD, Vyas P, Bandyopadhyay D, Prajapati V, Bahekar R, Patel PN, Kawade HM, Kokare DM, Pawar V, Desai R (2022) ZYKR1, a novel, potent, and peripherally selective kappa opioid receptor agonist reduces visceral pain and pruritus in animal models. Eur J Pharmacol. 924:174961. https:\/\/doi.org\/10.1016\/j.ejphar.2022.174961","journal-title":"Eur J Pharmacol."},{"issue":"4","key":"2912_CR15","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1016\/j.jpain.2015.01.341","volume":"16","author":"F Menzaghi","year":"2015","unstructured":"Menzaghi F, Spencer R, Abrouk N, Lewis M, Chalmers D (2015) (422) CR845, a peripheral kappa opioid, provides better pain relief with less nausea and vomiting than placebo in patients after bunionectomy. J Pain 16(4):S81. https:\/\/doi.org\/10.1016\/j.jpain.2015.01.341","journal-title":"J Pain"},{"key":"2912_CR16","unstructured":"Queremel Milani DA, Davis DD (2023) Pain Management Medications. [Updated 2023 Jul 3]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560692\/"},{"issue":"11","key":"2912_CR17","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1002\/j.1552-4604.1994.tb01991.x","volume":"34","author":"PA Reece","year":"1994","unstructured":"Reece PA, Sedman AJ, Rose S, Wright DS, Dawkins R, Rajagopalan R (1994) Diuretic effects, pharmacokinetics, and safety of a new centrally acting kappa-opioid agonist (CI-977) in humans. J Clin Pharmacol 34(11):1126\u20131132. https:\/\/doi.org\/10.1002\/j.1552-4604.1994.tb01991.x","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"2912_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3109\/07420528809078555","volume":"5","author":"J Salvador","year":"1988","unstructured":"Salvador J, Dieguez C, Scanlon MF (1988) The circadian rhythms of thyrotrophin and prolactin secretion. Chronobiol Int 5(1):85\u201393. https:\/\/doi.org\/10.3109\/07420528809078555","journal-title":"Chronobiol Int"},{"issue":"5","key":"2912_CR19","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1111\/cts.13042","volume":"14","author":"ER Viscusi","year":"2021","unstructured":"Viscusi ER, Torjman MC, Munera CL, Stauffer JW, Setnik BS, Bagal SN (2021) Effect of difelikefalin, a selective kappa opioid receptor agonist, on respiratory depression: a randomized, double-blind, placebo-controlled trial. Clin Transl Sci 14(5):1886\u20131893. https:\/\/doi.org\/10.1111\/cts.13042","journal-title":"Clin Transl Sci"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-023-02912-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-023-02912-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-023-02912-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T13:21:30Z","timestamp":1718112090000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-023-02912-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,23]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2912"],"URL":"https:\/\/doi.org\/10.1007\/s00210-023-02912-9","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,23]]},"assertion":[{"value":"29 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted at a single center at the Zydus Research Centre, Ahmedabad. This trial was initiated after obtaining the approvals of the EC and DCGI and registering the trial with the CTRI. This trial was conducted in accordance with the applicable local regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all the participants before enrolment in the clinical trial.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All the authors drafted the article and\/or revised it critically for important intellectual content and provided final approval of the published version.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All the authors are employees of Zydus Lifesciences Ltd. or its affiliate company. There are no known competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This report was prepared by the authors, who had full access to all data in the study and had final responsibility for the decision to submit the manuscript for publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclaimer"}}]}}